Skip to main content
Erschienen in: World Journal of Surgery 6/2013

01.06.2013

Aggressive Treatment for Hepatic Metastases from Breast Cancer: Results from a Single Center

verfasst von: F. Polistina, G. Costantin, A. Febbraro, E. Robusto, G. Ambrosino

Erschienen in: World Journal of Surgery | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer (BC) is the most common cancer among women worldwide. It has been estimated that approximately 12–20 % of patients will develop liver metastases from breast cancer (BCLM) and that in approximately 5 % of cases the liver is the only metastatic site. Patients with isolated BCLM have the poorest prognosis with a median survival ranging from 19 to 26 months.

Methods

A total of 26 women with isolated BCLM and without any sign of disease progression after a cycle of chemotherapy were retrospectively reviewed. Women were treated with hepatic resection (HR) for unilobar disease or surgical “open” RFA for bilobar disease. Data were collected on either original BC or BCLM and from patients follow-up.

Results

Overall survival from BC diagnosis was 47.69 ± 22.25 months (range 33–84, median 45.5 months); it was 52.25 ± 14.57 months (range 33–84, median 48.5 months) for the HR patients and 43.79 ± 27.14 months (range 9–101, median 39 months) for the RFA patients. Overall survival from BCLM treatment was 21.12 ± 12.78 months (range 9–64, median 15.5 months); in detail it was 29.42 ± 14.53 months (range 12–64, median 29.5 months) for the resected patients and 14 ± 4.45 months (range 9–24, median 13.5 months) for patients treated by RFA with a strongly significant survival difference for operated patients (p = 0.001). Overall disease-free survival from BCLM was 15.96 ± 13.16 months (range 3–64, median 12 months), disease-free survival for resected patients was 23.22 ± 16.2 months (range 8–64, median 18.5 months), and for patients treated by RFA was 9.64 ± 4.22 months (range 3–18, median 9 months; Fig. 1). Overall 1, 2, and 5 years (actuarial) survival was respectively 80.7, 57, and 31 %. Given in details for the two groups, they were respectively 100, 66.6 and 34 % (actuarial) for the resected group patients and 64.2, 21.4, and 11.5 % (actuarial) for the RFA patients.

Conclusions

Aggressive treatment on isolated BCLM may improve survival for these patients
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef
2.
Zurück zum Zitat Guarneri V, Conte PF (2009) Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 14:645–656PubMedCrossRef Guarneri V, Conte PF (2009) Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 14:645–656PubMedCrossRef
3.
Zurück zum Zitat Jardines L, Callans LS, Torosian MH (1993) Recurrent breast cancer: presentation, diagnosis and treatment. Semin Oncol 20:538–547PubMed Jardines L, Callans LS, Torosian MH (1993) Recurrent breast cancer: presentation, diagnosis and treatment. Semin Oncol 20:538–547PubMed
4.
Zurück zum Zitat Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81:1109–1112PubMedCrossRef Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81:1109–1112PubMedCrossRef
5.
Zurück zum Zitat Singletary SE, Walsh G, Vauthey JN et al (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8:241–251PubMedCrossRef Singletary SE, Walsh G, Vauthey JN et al (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8:241–251PubMedCrossRef
6.
Zurück zum Zitat Piccart MJ (2001) Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Annals of Oncology 12(Suppl 1):S89−S94 Piccart MJ (2001) Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Annals of Oncology 12(Suppl 1):S89−S94
7.
Zurück zum Zitat Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8(3):224–233PubMedCrossRef Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8(3):224–233PubMedCrossRef
8.
Zurück zum Zitat Pagani O, Senkus E, Wood W et al (2010) on behalf of the ESO–MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102(7):456–463PubMedCrossRef Pagani O, Senkus E, Wood W et al (2010) on behalf of the ESO–MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102(7):456–463PubMedCrossRef
9.
Zurück zum Zitat Elias D, Lasser P, Spielmann M, May-Levin F et al (1991) Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet 172(6):461–464PubMed Elias D, Lasser P, Spielmann M, May-Levin F et al (1991) Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet 172(6):461–464PubMed
10.
Zurück zum Zitat Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771–1785PubMedCrossRef Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771–1785PubMedCrossRef
11.
12.
Zurück zum Zitat Mulier S, Yicheng Ni, Jamart J et al (2005) Local recurrence after hepatic radiofrequency coagulation. Multivariate meta-analysis and review of contributing factors. Ann Surg 242(2):158–171PubMedCrossRef Mulier S, Yicheng Ni, Jamart J et al (2005) Local recurrence after hepatic radiofrequency coagulation. Multivariate meta-analysis and review of contributing factors. Ann Surg 242(2):158–171PubMedCrossRef
13.
Zurück zum Zitat Gillams A (2008) Tumor ablation: current role in the liver, kidney and bone. Cancer Imaging 8:S1–S5PubMedCrossRef Gillams A (2008) Tumor ablation: current role in the liver, kidney and bone. Cancer Imaging 8:S1–S5PubMedCrossRef
14.
Zurück zum Zitat Yun BL, Lee JM, Baek JH et al (2011) Radiofrequency ablation for treating liver metastases from a non-colorectal origin. Korean J Radiol 12(5):579–587PubMedCrossRef Yun BL, Lee JM, Baek JH et al (2011) Radiofrequency ablation for treating liver metastases from a non-colorectal origin. Korean J Radiol 12(5):579–587PubMedCrossRef
15.
Zurück zum Zitat Mulier S, Ni Y, Jamart J et al (2008) Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol 15(1):144–157PubMedCrossRef Mulier S, Ni Y, Jamart J et al (2008) Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol 15(1):144–157PubMedCrossRef
16.
Zurück zum Zitat Sutherland LM, Williams JAR, Padbury RTA et al (2006) Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141:181–190PubMedCrossRef Sutherland LM, Williams JAR, Padbury RTA et al (2006) Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141:181–190PubMedCrossRef
17.
Zurück zum Zitat Illing R, Gillams A (2010) Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol (R Coll Radiol) 22(9):781–784CrossRef Illing R, Gillams A (2010) Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol (R Coll Radiol) 22(9):781–784CrossRef
18.
Zurück zum Zitat Raab R, Nussbaum KT, Behrend M et al (1998) Liver metastases of breast cancer: results of liver resection. Anticancer Res 18:2231–2233PubMed Raab R, Nussbaum KT, Behrend M et al (1998) Liver metastases of breast cancer: results of liver resection. Anticancer Res 18:2231–2233PubMed
19.
Zurück zum Zitat Seifert JK, Weigel TF, Gonner U et al (1999) Liver resection for breast cancer metastases. Hepatogastroenterology 46:2935–2940PubMed Seifert JK, Weigel TF, Gonner U et al (1999) Liver resection for breast cancer metastases. Hepatogastroenterology 46:2935–2940PubMed
20.
Zurück zum Zitat Selzner M, Morse MA, Vredenburgh JJ et al (2000) Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127:383–389PubMedCrossRef Selzner M, Morse MA, Vredenburgh JJ et al (2000) Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127:383–389PubMedCrossRef
21.
Zurück zum Zitat Yoshimoto M, Tada T, Saito M et al (2000) Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat 59:177–184PubMedCrossRef Yoshimoto M, Tada T, Saito M et al (2000) Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat 59:177–184PubMedCrossRef
22.
Zurück zum Zitat Pocard M, Pouillart P, Asselain B et al (2001) Hepatic resection for breast cancer metastases: results and prognosis (65 cases). Ann Chir 126:413–420PubMedCrossRef Pocard M, Pouillart P, Asselain B et al (2001) Hepatic resection for breast cancer metastases: results and prognosis (65 cases). Ann Chir 126:413–420PubMedCrossRef
23.
Zurück zum Zitat Carlini M, Lonardo MT, Carboni F et al (2002) Liver metastases from breast cancer: results of surgical resection. Hepatogastroenterology 49:1597–1601PubMed Carlini M, Lonardo MT, Carboni F et al (2002) Liver metastases from breast cancer: results of surgical resection. Hepatogastroenterology 49:1597–1601PubMed
24.
Zurück zum Zitat Elias D, Maisonnette F, Druet-Cabanac M et al (2003) An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 185:158–164PubMedCrossRef Elias D, Maisonnette F, Druet-Cabanac M et al (2003) An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 185:158–164PubMedCrossRef
25.
Zurück zum Zitat Vlastos G, Smith DL, Singletary SE et al (2004) Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11:869–874PubMedCrossRef Vlastos G, Smith DL, Singletary SE et al (2004) Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11:869–874PubMedCrossRef
26.
Zurück zum Zitat Sakamoto Y, Yamamoto J, Yoshimoto M et al (2005) Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg 29:524–527PubMedCrossRef Sakamoto Y, Yamamoto J, Yoshimoto M et al (2005) Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg 29:524–527PubMedCrossRef
27.
Zurück zum Zitat Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–907PubMedCrossRef Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–907PubMedCrossRef
28.
Zurück zum Zitat Furka A, Halasz L, Szentkereszty Z et al (2008) Surgical treatment of liver metastases from breast cancer. Hepatogastroenterology 55:1416–1418PubMed Furka A, Halasz L, Szentkereszty Z et al (2008) Surgical treatment of liver metastases from breast cancer. Hepatogastroenterology 55:1416–1418PubMed
29.
Zurück zum Zitat Caralt M, Bilbao I, Cortes J et al (2008) Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol 15:2804–2810PubMedCrossRef Caralt M, Bilbao I, Cortes J et al (2008) Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol 15:2804–2810PubMedCrossRef
30.
Zurück zum Zitat Lubrano J, Roman H, Tarrab S et al (2008) Liver resection for breast cancer metastasis: does it improve survival? Surg Today 38:293–299PubMedCrossRef Lubrano J, Roman H, Tarrab S et al (2008) Liver resection for breast cancer metastasis: does it improve survival? Surg Today 38:293–299PubMedCrossRef
31.
Zurück zum Zitat Thelen A, Benckert C, Jonas S et al (2008) Liver resection for metastases from breast cancer. J Surg Oncol 97:25–29PubMedCrossRef Thelen A, Benckert C, Jonas S et al (2008) Liver resection for metastases from breast cancer. J Surg Oncol 97:25–29PubMedCrossRef
32.
Zurück zum Zitat Chua TC, Saxena A, Liauw W et al (2011) Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 47(15):2282–2290PubMedCrossRef Chua TC, Saxena A, Liauw W et al (2011) Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 47(15):2282–2290PubMedCrossRef
33.
Zurück zum Zitat Rubino A, Doci R, Foteuh JC et al (2010) Hepatic metastases from breast cancer. Updates Surg 62(3–4):143–148PubMedCrossRef Rubino A, Doci R, Foteuh JC et al (2010) Hepatic metastases from breast cancer. Updates Surg 62(3–4):143–148PubMedCrossRef
34.
Zurück zum Zitat Hoffmann K, Franz C, Hinz U et al (2010) Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol 17(6):1546–1554PubMedCrossRef Hoffmann K, Franz C, Hinz U et al (2010) Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol 17(6):1546–1554PubMedCrossRef
35.
Zurück zum Zitat Penthereoudakis G, Fountzilas G, Bafaloukos D et al (2006) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97(3):237–244CrossRef Penthereoudakis G, Fountzilas G, Bafaloukos D et al (2006) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97(3):237–244CrossRef
36.
Zurück zum Zitat Rodes BS, Martin RC 2nd (2012) Management of liver metastatic breast cancer: surgery, chemotherapy or hepatic arterial therapy- benefits and limitations. Minerva Chir 67(4):297–308 Rodes BS, Martin RC 2nd (2012) Management of liver metastatic breast cancer: surgery, chemotherapy or hepatic arterial therapy- benefits and limitations. Minerva Chir 67(4):297–308
37.
Zurück zum Zitat Gunabushanam G, Sharma S, Thulkar S et al (2007) Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol 18(1 pt 1):67–72PubMedCrossRef Gunabushanam G, Sharma S, Thulkar S et al (2007) Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol 18(1 pt 1):67–72PubMedCrossRef
38.
Zurück zum Zitat Jakobs TF, Hoffmann RT, Schader A et al (2009) CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 32(1):38–46PubMedCrossRef Jakobs TF, Hoffmann RT, Schader A et al (2009) CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 32(1):38–46PubMedCrossRef
39.
Zurück zum Zitat Lawes D, Chopada A, Gillams A et al (2006) Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastases from breast cancer. Ann R Coll Surg Engl 88(7):639–642PubMedCrossRef Lawes D, Chopada A, Gillams A et al (2006) Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastases from breast cancer. Ann R Coll Surg Engl 88(7):639–642PubMedCrossRef
40.
Zurück zum Zitat Livraghi T, Goldberg SN, Solbiati L et al (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer. Initial experience in 24 patients. Radiology 220:145–149PubMed Livraghi T, Goldberg SN, Solbiati L et al (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer. Initial experience in 24 patients. Radiology 220:145–149PubMed
41.
Zurück zum Zitat Meloni MF, Andreano A, Laeseke PF et al (2009) Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long term survival rates. Radiology 253:861–869PubMedCrossRef Meloni MF, Andreano A, Laeseke PF et al (2009) Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long term survival rates. Radiology 253:861–869PubMedCrossRef
42.
Zurück zum Zitat Abbott E, Brouquet A, Mittendorf EA et al (2012) Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710–716PubMedCrossRef Abbott E, Brouquet A, Mittendorf EA et al (2012) Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710–716PubMedCrossRef
43.
Zurück zum Zitat Martinez SR, Young SE, Giuliano AE et al (2006) The utility of estrogen receptor, and HER-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am J Surg 191:281–283PubMedCrossRef Martinez SR, Young SE, Giuliano AE et al (2006) The utility of estrogen receptor, and HER-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am J Surg 191:281–283PubMedCrossRef
44.
Zurück zum Zitat Van Walsum GA, de Ridder JA, Verhoef C et al (2012) Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 38(10):910–917PubMedCrossRef Van Walsum GA, de Ridder JA, Verhoef C et al (2012) Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 38(10):910–917PubMedCrossRef
45.
Zurück zum Zitat Lumachi F, Basso SMM, Marino F et al (2011) Relationship between survival, hormone receptor rate, and Ca 15–3 serum levels in patients with isolated liver metastases from breast cancer. Eur J Cancer 47(Suppl 1):S360CrossRef Lumachi F, Basso SMM, Marino F et al (2011) Relationship between survival, hormone receptor rate, and Ca 15–3 serum levels in patients with isolated liver metastases from breast cancer. Eur J Cancer 47(Suppl 1):S360CrossRef
46.
Zurück zum Zitat Chua TC, Saxena A, Liauw W et al (2011) Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 47:2282–2290PubMedCrossRef Chua TC, Saxena A, Liauw W et al (2011) Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 47:2282–2290PubMedCrossRef
47.
Zurück zum Zitat Azam M, Qureshi A, Mansoor S (2009) Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. J Pak Med Assoc 59(11):736–740PubMed Azam M, Qureshi A, Mansoor S (2009) Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. J Pak Med Assoc 59(11):736–740PubMed
48.
Zurück zum Zitat Aitken SJ, Thomas S, Langdon SP et al (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21:1254–1261PubMedCrossRef Aitken SJ, Thomas S, Langdon SP et al (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21:1254–1261PubMedCrossRef
49.
Zurück zum Zitat Idirisinghe PK, Thike AA, Cheok PY et al (2010) Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 133(3):416–429PubMedCrossRef Idirisinghe PK, Thike AA, Cheok PY et al (2010) Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 133(3):416–429PubMedCrossRef
50.
Zurück zum Zitat Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254–1261PubMedCrossRef Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254–1261PubMedCrossRef
51.
Zurück zum Zitat Gerson R, Alban F, Villalobos A et al (2008) Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype. Gac Med Mex 144(1):27–34PubMed Gerson R, Alban F, Villalobos A et al (2008) Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype. Gac Med Mex 144(1):27–34PubMed
52.
Zurück zum Zitat Chen XS, Ma CD, Wu JY et al (2010) Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict prognosis of breast cancer. Tumori 96(1):103–110PubMed Chen XS, Ma CD, Wu JY et al (2010) Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict prognosis of breast cancer. Tumori 96(1):103–110PubMed
53.
Zurück zum Zitat Aspitia AM, Perez EA (2009) Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 84(6):533–545CrossRef Aspitia AM, Perez EA (2009) Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 84(6):533–545CrossRef
Metadaten
Titel
Aggressive Treatment for Hepatic Metastases from Breast Cancer: Results from a Single Center
verfasst von
F. Polistina
G. Costantin
A. Febbraro
E. Robusto
G. Ambrosino
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 6/2013
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-013-1986-9

Weitere Artikel der Ausgabe 6/2013

World Journal of Surgery 6/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.